Brief: Cabaletta Bio Receives FDA Clearance Of Ind Application For Caba-201 For Treatment Of Systemic Lupus Erythematosus
31/03/2023 12:08
March 31 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES FDA CLEARANCE OF IND APPLICATION
FOR
CABA-201 FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
* CABALETTA BIO INC - PLANS TO INITIATE A PHASE 1/2 CLINICAL
TRIAL
OF CABA-201 FOR TREATMENT OF SLE IN PATIENTS WITH ACTIVE LUPUS
NEPHRITIS
Source text for Eikon: ID:nGNX4227FQ
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview